Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels.
Soins de soutienHydratation
#5
Y a-t-il des traitements spécifiques pour les effets chroniques ?
Les traitements des effets chroniques incluent la réhabilitation et le suivi médical.
RéhabilitationSuivi médical
Complications
5
#1
Quelles complications peuvent survenir après exposition ?
Des complications incluent des troubles hépatiques, rénaux et neurologiques.
ComplicationsTroubles hépatiques
#2
Y a-t-il des risques de cancer associés ?
Une exposition prolongée peut augmenter le risque de certains cancers.
CancerExposition prolongée
#3
Comment les complications sont-elles surveillées ?
Des examens médicaux réguliers et des tests de fonction organique sont nécessaires.
Surveillance médicaleTests de fonction
#4
Les complications peuvent-elles être réversibles ?
Certaines complications peuvent être réversibles avec un traitement précoce.
Complications réversiblesTraitement précoce
#5
Quels sont les effets à long terme possibles ?
Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels.
Effets à long termeTroubles chroniques
Facteurs de risque
5
#1
Qui est le plus à risque d'exposition ?
Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque.
TravailleursIndustrie chimique
#2
Quels environnements augmentent le risque ?
Les environnements de travail mal ventilés et non sécurisés augmentent le risque.
Environnements de travailVentilation
#3
Y a-t-il des facteurs génétiques impliqués ?
Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité.
Facteurs génétiquesSusceptibilité
#4
Comment l'âge influence-t-il le risque ?
Les personnes âgées peuvent être plus vulnérables aux effets toxiques.
ÂgeVulnérabilité
#5
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque.
Antécédents médicauxMaladies hépatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "1,1',1''-Phosphoryltriaziridine : Questions médicales les plus fréquentes",
"headline": "1,1',1''-Phosphoryltriaziridine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 1,1',1''-Phosphoryltriaziridine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-09",
"dateModified": "2025-04-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aziridines",
"url": "https://questionsmedicales.fr/mesh/D001388",
"about": {
"@type": "MedicalCondition",
"name": "Aziridines",
"code": {
"@type": "MedicalCode",
"code": "D001388",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Thiotépa",
"alternateName": "Thiotepa",
"url": "https://questionsmedicales.fr/mesh/D013852",
"about": {
"@type": "MedicalCondition",
"name": "Thiotépa",
"code": {
"@type": "MedicalCode",
"code": "D013852",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.097.217.935.960"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "1,1',1''-Phosphoryltriaziridine",
"alternateName": "Triethylenephosphoramide",
"code": {
"@type": "MedicalCode",
"code": "D013721",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liusheng Huang",
"url": "https://questionsmedicales.fr/author/Liusheng%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Beth Apsel Winger",
"url": "https://questionsmedicales.fr/author/Beth%20Apsel%20Winger",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, University of California San Francisco."
}
},
{
"@type": "Person",
"name": "Vincent Cheah",
"url": "https://questionsmedicales.fr/author/Vincent%20Cheah",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "David Gingrich",
"url": "https://questionsmedicales.fr/author/David%20Gingrich",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
},
{
"@type": "Person",
"name": "Florence Marzan",
"url": "https://questionsmedicales.fr/author/Florence%20Marzan",
"affiliation": {
"@type": "Organization",
"name": "Drug Research Unit, Department of Clinical Pharmacy, University of California San Francisco, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Comparing ICD-11 and DSM-5 eating disorder diagnoses with the Munich eating and feeding disorder questionnaire (ED-Quest).",
"datePublished": "2023-06-13",
"url": "https://questionsmedicales.fr/article/37309255",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/eat.24010"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prospective associations between early childhood parental feeding practices and eating disorder symptoms and disordered eating behaviors in adolescence.",
"datePublished": "2024-02-22",
"url": "https://questionsmedicales.fr/article/38387486",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/eat.24159"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pediatric Intestinal Failure Associated Eating Disorder: An Overview of the Importance of Oral Feeding in a Population at Risk for Feeding Difficulties.",
"datePublished": "2024-02-01",
"url": "https://questionsmedicales.fr/article/38719381",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gtc.2023.12.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of educational interventions in adolescent population with feeding and eating disorders: a systematic review.",
"datePublished": "2023-08-22",
"url": "https://questionsmedicales.fr/article/37608142",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40519-023-01594-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Disordered Eating/Eating Disorders in Adolescents.",
"datePublished": "2024-05-08",
"url": "https://questionsmedicales.fr/article/39003006",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pcl.2024.04.005"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Azirines",
"item": "https://questionsmedicales.fr/mesh/D001389"
},
{
"@type": "ListItem",
"position": 5,
"name": "Aziridines",
"item": "https://questionsmedicales.fr/mesh/D001388"
},
{
"@type": "ListItem",
"position": 6,
"name": "1,1',1''-Phosphoryltriaziridine",
"item": "https://questionsmedicales.fr/mesh/D013721"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 1,1',1''-Phosphoryltriaziridine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?\nQuels tests sont utilisés pour évaluer la toxicité ?\nQuels symptômes indiquent une intoxication ?\nY a-t-il des marqueurs biologiques spécifiques ?\nComment évaluer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Feeding+and+Eating+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quels sont les symptômes d'une exposition aiguë ?\nPeut-on avoir des symptômes neurologiques ?\nQuels symptômes digestifs peuvent apparaître ?\nY a-t-il des symptômes cutanés associés ?\nComment les symptômes évoluent-ils dans le temps ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Feeding+and+Eating+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 1,1',1''-Phosphoryltriaziridine",
"description": "Comment prévenir l'exposition au Triethylenephosphoramide ?\nQuelles formations sont nécessaires pour les travailleurs ?\nQuels sont les protocoles de sécurité recommandés ?\nComment gérer les déchets contenant ce composé ?\nY a-t-il des recommandations pour les laboratoires ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Feeding+and+Eating+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quel est le traitement principal en cas d'intoxication ?\nDes antidotes existent-ils pour ce composé ?\nComment traiter les symptômes neurologiques ?\nQuelles mesures de soutien sont recommandées ?\nY a-t-il des traitements spécifiques pour les effets chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Feeding+and+Eating+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 1,1',1''-Phosphoryltriaziridine",
"description": "Quelles complications peuvent survenir après exposition ?\nY a-t-il des risques de cancer associés ?\nComment les complications sont-elles surveillées ?\nLes complications peuvent-elles être réversibles ?\nQuels sont les effets à long terme possibles ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Feeding+and+Eating+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 1,1',1''-Phosphoryltriaziridine",
"description": "Qui est le plus à risque d'exposition ?\nQuels environnements augmentent le risque ?\nY a-t-il des facteurs génétiques impliqués ?\nComment l'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D013721?mesh_terms=Feeding+and+Eating+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une exposition au Triethylenephosphoramide ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests biologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la toxicité ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses d'urine peuvent détecter des métabolites toxiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme les enzymes hépatiques peuvent indiquer une toxicité."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets à long terme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des évaluations cliniques sont nécessaires pour détecter des effets chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une exposition aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes aigus incluent des maux de tête, des vertiges et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes neurologiques comme des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels symptômes digestifs peuvent apparaître ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées, vomissements et diarrhées sont fréquents après exposition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des irritations peuvent se manifester après contact."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils dans le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si l'exposition se poursuit."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au Triethylenephosphoramide ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles formations sont nécessaires pour les travailleurs ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations sur la manipulation sécurisée des produits chimiques sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels sont les protocoles de sécurité recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les protocoles incluent des procédures d'urgence et des contrôles d'exposition réguliers."
}
},
{
"@type": "Question",
"name": "Comment gérer les déchets contenant ce composé ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déchets doivent être éliminés selon les réglementations en vigueur pour les produits toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les laboratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les laboratoires doivent avoir des systèmes de ventilation et des douches de sécurité."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'élimination de l'exposition et le soutien symptomatique."
}
},
{
"@type": "Question",
"name": "Des antidotes existent-ils pour ce composé ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique."
}
},
{
"@type": "Question",
"name": "Comment traiter les symptômes neurologiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes neurologiques peuvent nécessiter des médicaments anticonvulsivants."
}
},
{
"@type": "Question",
"name": "Quelles mesures de soutien sont recommandées ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien, comme l'hydratation et le monitoring, sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les effets chroniques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements des effets chroniques incluent la réhabilitation et le suivi médical."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après exposition ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles hépatiques, rénaux et neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de cancer associés ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut augmenter le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles surveillées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens médicaux réguliers et des tests de fonction organique sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement précoce."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets à long terme peuvent inclure des troubles chroniques et des déficits fonctionnels."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs dans l'industrie chimique et les laboratoires sont les plus à risque."
}
},
{
"@type": "Question",
"name": "Quels environnements augmentent le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les environnements de travail mal ventilés et non sécurisés augmentent le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques impliqués ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs génétiques peuvent influencer la susceptibilité à la toxicité."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées peuvent être plus vulnérables aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies hépatiques ou rénales augmentent le risque."
}
}
]
}
]
}
The new ICD-11 eating disorders (ED) guidelines are similar to the DSM-5 criteria. One difference to the DSM-5 is the inclusion of subjective binges in the definition of bulimia nervosa (BN) and binge...
Data of 3863 ED inpatients who completed the Munich Eating and Feeding Disorder Questionnaire were analyzed using standardized diagnostic algorithms for DSM-5 and ICD-11....
Agreement of diagnoses was high (Krippendorff's α = .88, 95% CI [.86, .89]) for anorexia nervosa (AN; 98.9%), BN (97.2%) and BED (100%), and lower for other feeding and eating disorders (OFED; 75.2%)....
For over 90% of patients, applying either DSM-5 or ICD-11 diagnostic criteria/guidelines resulted in the same full-threshold ED diagnosis. Sub-threshold and feeding disorders exhibited a discrepancy o...
For about 98% of inpatients, the ICD-11 and DSM-5 agree on the same specified eating disorder diagnosis. This is important when comparing diagnoses made by different diagnostic systems. Including subj...
Nonresponsive parental feeding practices are associated with poorer appetite self-regulation in children. It is unknown whether this relationship extends beyond childhood to be prospectively associate...
Data were from two population-based cohorts with harmonized measures: Generation R (Netherlands; n = 4900) and Gemini (UK; n = 2094). Parents self-reported their pressure to eat, restriction and instr...
In Gemini, pressure to eat in early childhood was associated with adolescents engaging in compensatory behaviors. In Generation R, parental restriction was associated with adolescents engaging in comp...
Nonresponsive parental feeding practices were associated with a greater frequency of specific ED symptoms and disordered eating in adolescence, although effect sizes were small and findings were incon...
Prospective research examining how early childhood parental feeding practices might contribute to adolescent ED symptoms is limited. In two population-based cohorts, nonresponsive feeding practices (r...
Achieving feeding skills and food acceptance is a multi-layered process. In pediatric intestinal failure (PIF), oral feeding is important for feeding skills development, physiologic adaptation, qualit...
Educational interventions are a key element in the care of young patients with feeding and eating disorders, forming part of the majority of therapeutic approaches. The aim of this review is to evalua...
Following the PRISMA recommendations electronic databases were searched up to 29 June 2023. Studies related to educational interventions in young population diagnosed with feeding and eating disorders...
A total of 191 articles were selected from the 9744 citations screened. Ten publications were included. The results indicated variability between educational programs, including individual and group i...
The results indicate that educational interventions can influence the improvement of knowledge level and have a positive effect on health outcomes. Although education is a common practice in the treat...
Level I: Systematic review....
The coronavirus disease 2019 pandemic was as tressful time for adolescents, with increased isolation, loss of routines, and changes in access to medical care. In this setting, the medical system saw a...
The incidence of feeding and eating problems and disorders (FEPD) in children increased during the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study was to assess the impact of the C...
Cross-sectional survey: parents of children with FEPD (0-11 years) in the Netherlands completed an online questionnaire (January-April 2021). This questionnaire included 4 demographic questions (inclu...
In total, 240 children (median age, 5.5 years; interquartile range [IQR], 3.5-7.9 years; 53.3% female) were included; 129 children with FEPD and 111 HC. Most children with FEPD fulfilled criteria for ...
It seems that the COVID-19 pandemic had great impact on young children with FEPD and their parents because parents of children with FEPD reported significantly more perceived stress within both the ch...
Although preliminary studies support the roles of unhealthy parenting styles and maladaptive coping styles in increasing rates of disturbed eating attitudes and behaviors (EAB) and clinically signific...
A total of 102 patients with FED in Zahedan, Iran, participating in this cross-sectional study (from April to March 2022) completed a sociodemographic information form and self-report measures of pare...
The results showed that authoritarian parenting style, overcompensation and avoidance coping styles, and female gender might be related to disturbed EAB. The overall hypothesis that overcompensation a...
Our findings highlighted the necessity of evaluating particular unhealthy parenting styles and maladaptive coping styles as the important possible risk factors in the development and maintenance of hi...
Eating disorders (EDs) are mental illnesses impacting all aspects of an individual's life. Recent research has examined EDs and disordered-eating behaviors in the military, a population subject to bod...
PubMed and PsycINFO were reviewed for relevant articles. All studies including data on EDs or disordered eating in U.S. active-duty, ROTC, or veteran populations were considered....
Results revealed a high burden of EDs and disordered eating with bulimic- and binge-type behaviors being the most common. Servicemembers exposed to trauma, including military sexual assault, and those...
The high prevalence of EDs and disordered eating in the military points toward the importance of identification, treatment, and prevention. Policy change is necessary to protect servicemembers....
Eating disorders, such as anorexia, bulimia and binge eating disorder, are a common mental health problem, but are even so easily missed in the medical field. Patients experience a lot of shame to com...
Anorexia nervosa (AN) and bulimia nervosa (BN) are easily missed in the emergency department, because patients may present with either low, normal, or increased BMI. Careful examination for signs of p...